Table 1.

Baseline characteristics of studies included in the network meta-analysis of patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer.

Study	Phase	Region	Sample Size (No.)	Intervention Arm	Control Arm	EGFR Mutation
						19del	L858R
Y. Cheng et al. 2016 [26,27]	II	East Asia	126/65	Pemetrexed 500 mg/m2 every 3 weeks + gefitinib 250 mg once a day	Gefitinib 250 mg once a day	65/40	52/23
C. An et al. 2016 [28]	II	China	45/45	Pemetrexed 500 mg/m2 every 3 weeks + gefitinib 250 mg once a day	Placebo 500 mg/m2 every 3 weeks + gefitinib 250 mg once a day	16/17	29/28
B. Han et al. 2017 [29,30]	II	China	40/41	Pemetrexed 500 mg/m2 + carboplatin (AUC 5) every 3 weeks + gefitinib 250 mg/day once a day	Gefitinib 250 mg once a day	21/21	19/20
L. Xu et al. 2019 [31]	II	China	90/89	Pemetrexed 500 mg/m2 + carboplatin (AUC 5) every 3 weeks + icotinib 125 mg, three times a day	Icotinib 125 mg, three times a day	51/52	38/37
Y. Hosomi et al. 2019 [32]	III	Japan	169/172	Pemetrexed 500 mg/m2 + carboplatin (AUC 5) every 3 weeks + gefitinib 250 mg/day once a day	Gefitinib 250 mg once a day	93/95	69/67
V. Noronha et al. 2019 [33]	III	India	174/176	Pemetrexed 500 mg/m2 + carboplatin (AUC 5) every 3 weeks + gefitinib 250 mg/day once a day	Gefitinib 250 mg once a day	107/109	60/60
T. Seto et al. 2014 [34,35,36]	II	Japan	75/77	Erlotinib 150 mg once a day + bevacizumab 15 mg/kg every 3 week	Erlotinib 150 mg once a day	40/40	35/37
H. Saito et al. 2019 [37,38]	III	Japan	112/112	Erlotinib 150 mg once a day + bevacizumab 15 mg/kg every 3 week	Erlotinib 150 mg once a day	56/55	56/57
T. E. Stinchcombe et al. 2019 [36]	II	America	43/45	Erlotinib 150 mg once a day + bevacizumab 15 mg/kg every 3 week	Erlotinib 150 mg once a day	29/30	14/15
Q. Zhou et al. 2021 [39]	III	China	157/154	Erlotinib 150 mg once a day + bevacizumab 15 mg/kg every 3 week	Erlotinib 150 mg once a day	82/79	75/75
K. Nakagawa et al. 2019 [40]	III	Global	224/225	Erlotinib 150 mg once a day + ramucirumab 10 mg/kg every 2 week	Erlotinib 150 mg once a day + placebo 10 mg/kg every 2 week	123/120	99/105
M. C. Piccirillo et al. 2022 [41]	III	Italy	80/80	Erlotinib 150 mg once a day + bevacizumab 15 mg/kg every 3 week	Erlotinib 150 mg once a day	44/44	34/32
X. Gu et al. 2011 [42]	II	China	18/18	Gefitinib 250 mg once a day + cryoablation	Gefitinib 250 mg once a day	NA	NA
B. Yu et.al. 2019 [43]	II	China	55/55	Gefitinib 250 mg once a day + microwave ablation	Gefitinib 250 mg once a day	NA	NA
N. B. Leighl et al. 2017 [44]	II	Global	44/44	Erlotinib 150 mg once a day + linsitinib 150 mg twice a day	Placebo 150 mg twice daily plus erlotinib 150 mg once daily	26/25	18/19
L. Li et al. 2019 [45]	II	China	112/111	Gefitinib 250 mg once a day + metformin was 500 mg after meal daily	Gefitinib 250 mg once a day	54/61	53/43
R. G. Campelo et al. 2020 [46]	II	Spain and Mexico	91/91	Gefitinib 250 mg once a day + olaparib 200 mg every 28-day	Gefitinib 250 mg once a day	57/52	25/35
X. Zheng et al. 2016 [47]	II	China	38/38	Erlotinib 150 mg once a day or icotinib 125 mg three times a day + 3D conformal radiation	Erlotinib 150 mg once a day or Icotinib 125 mg three times a day	22/21	18/17
X. Wang et al. 2022 [48]	III	China	68/65	Gefitinib 250 mg once a day or erlotinib 150 mg once a day or icotinib 125 mg three times a day + radiation	Gefitinib 250 mg once a day or erlotinib 150 mg once a day or icotinib 125 mg three times a day	45/47	23/18
Y. Qiu et al. 2020 [49]	II	China	21/21	Icotinib 125 mg three times a day + radiotherapy and GM-CSF	Icotinib 125 mg three times a day	15/13	6/8
S. B. Goldberg et al. 2020 [50]	II	America	83/85	Afatinib 40 mg once a day + cetuximab 500 mg/m2 every 2 weeks	Afatinib 40 mg once a day	53/54	30/31
A. B. Cortot et al. 2021 [51]	II	France	58/59	Afatinib 40 mg once a day + cetuximab 500 mg/m2 every 2 weeks	Afatinib 40 mg once a day	32/33	24/23
H. Kenmotsu et al. 2022 [52]	II	Japan	61/61	Osimertinib 80 mg once a day + bevacizumab 15 mg/kg every 3 week	Osimertinib 80 mg once a day	35/36	26/25

Data are expressed as intervention/control, unless otherwise indicated. NA: not available; GM-CSF: granulocyte macrophage colony-stimulating factor.